Natalia Elizalde, Chief Business Development Officer at VIVEbiotech, shares her thoughts on strategies the company employs to reduce time-to-market as demanded by the biopharmaceutical industry.

As Natalia notes, VIVEbiotech utilizes a very well-established fixed-bed reactor platform that allows efficient scale-up. This platform, with over 150 batches produced under FDA´s and EMA´s regulations, allows seamless tech transfer and quick scalability. Additionally, she points out how the company’s large lentiviral vector program ensures ample capacity, preventing delays in crucial stages. Natalia concludes saying VIVEbiotech prioritizes stability by maintaining a highly skilled and stable team with a turnover rate below 5%, which also contributes to reducing unforeseen delays in project execution.

To know more about the strategies other industry experts mention, read the full article here:

Many thanks to Pharma’s Almanac for this opportunity and the resulting great piece.